I am pleased to share that Memorial Sloan Kettering Cancer Center’s state-of-the-art cancer care  pavilion currently under construction will be named The Kenneth C. Griffin Pavilion at Memorial Sloan Kettering Cancer Center. We are deeply grateful to Ken for his extraordinary generosity and all he

bsky.app/profile/scotni… Follow me on blue sky. ScotNiglio.bsky.social I’m moving platforms.

US FDA approves durvalumab in muscle invasive bladder cancer of off NIAGARA. Congratulations to Tom Powles and the investigators on the study. fda.gov/drugs/resource…

We are thrilled to announce the appointment of Alec C. Kimmelman, MD, PhD, as the next Chief Executive Officer at NYU Langone Health and Dean of NYU Grossman School of Medicine effective September 1, 2025. Learn more: nyulangone.org/news/nyu-lango…

nature.com/articles/d4158… nature

🧩 ctDNA is a key piece of the puzzle in building an integrated precision oncology ecosystem at Weill Cornell Medicine Excited to share collaborative paper #2 this month. This time with the brilliant Alexandre Pellan Cheng & Dan Landau! rdcu.be/ehkUb Nature Methods Highlights: 🔬

Insert pic of me on a plane here 🙂

Tomorrow! ASCO #ASCO25 OncoAlert Bladder Cancer Advocacy Network UroToday.com NewYork-Presbyterian Weill Cornell Medicine

Updated data from #PSMA monitoring study in #BCR #ProstateCancer ASCO #ASCO25 Stop by & see our poster on Monday morning You can see what happens to this pt at 6 months 10+ LNs How would you have managed this case? Trial continues to accrue National Cancer Institute clinicaltrials.gov/study/NCT05588…

Devastating cut to National Cancer Institute budget - sad to see US cancer research de-prioritized in this time of tremendous potential and innovation #ASCO25

Matt Galsky discusses the ctDNA data from NIAGARA presented at #ASCO25. ctDNA positivity is distinct from path CR and ctDNA positive patients do poorly creators.spotify.com/pod/show/the-u…

The most robust data post EVP in M1 bladder cancer by Michal Sternschuss MSKCC Carboplatin/gem was the commonest regimen #ASCO25 OncoAlert Results showed ⬆️ RRs than expected (50%) PFS =4.5 months & OS =11 months are good. 1st line gem/carbo OS was ~10 months previously?

Great job Michal

🔬 CONTACT-02 Phase 3 Trial in mCRPC 🔬 📍 Patients with metastatic castration-resistant prostate cancer + extrapelvic soft-tissue mets post-ARPI 💊 Cabozantinib + Atezolizumab vs ARPI switch ✅ PFS: 6.3 vs 4.2 mo (HR 0.65, P=0.0007) ❌ OS: No significant difference (14.8 vs

All that you can’t leave behind on MIBC is online Journal of Clinical Oncology ASCO @MattGalsky Ashish M. Kamat, MD, MBBS Leslie Ballas Muscle-Invasive Bladder Cancer: A Watershed Moment | Journal of Clinical Oncology ascopubs.org/doi/abs/10.120…

merck.com/news/keytruda-… Ashish M. Kamat, MD, MBBS UroToday.com Uromigos Bladder Cancer Advocacy Network IBCG

Important to distinguish #serosal findings on #PSMA 🩻vs. #parenchymal Serosal lesions are better seen on #PSMA vs CT/MRI in #ProstateCancer but likely have an indolent course even with no 🚫therapy (even on the liver!) Melissa Abel, MD et al.Nature Reviews Urology rdcu.be/eBwPs

Praying for everyone’s safety Villanova University

LATEST: Villanova University said news of a possible shooter at its law school was a "cruel hoax," after it issued an alert warning of an active shooter on its Pennsylvania campus. abcnews.link/9Mcyg0M